Display options
Cite
Pavlidou A, Kroupis C, Dimas K. Association of survivin splice variants with prognosis and treatment of breast cancer. World J Clin Oncol. 2014;5(5):883-94doi: 10.5306/wjco.v5.i5.883.
Pavlidou, A., Kroupis, C., & Dimas, K. (2014). Association of survivin splice variants with prognosis and treatment of breast cancer. World journal of clinical oncology, 5(5), 883-94. https://doi.org/10.5306/wjco.v5.i5.883
Pavlidou, Anastasia, et al. "Association of survivin splice variants with prognosis and treatment of breast cancer." World journal of clinical oncology vol. 5,5 (2014): 883-94. doi: https://doi.org/10.5306/wjco.v5.i5.883
Pavlidou A, Kroupis C, Dimas K. Association of survivin splice variants with prognosis and treatment of breast cancer. World J Clin Oncol. 2014 Dec 10;5(5):883-94. doi: 10.5306/wjco.v5.i5.883. PMID: 25493226; PMCID: PMC4259950.
Copy Download .nbib Format: NLM
Share it on

World J Clin Oncol. 2014 Dec 10;5(5):883-94. doi: 10.5306/wjco.v5.i5.883.

Association of survivin splice variants with prognosis and treatment of breast cancer.

World journal of clinical oncology

Anastasia Pavlidou, Christos Kroupis, Kleanthi Dimas

Affiliations

  1. Anastasia Pavlidou, Christos Kroupis, Kleanthi Dimas, Department of Clinical Biochemistry, Attikon University General Hospital, Haidari 12462, Greece.

PMID: 25493226 PMCID: PMC4259950 DOI: 10.5306/wjco.v5.i5.883

Abstract

The purpose of this study was the overview of current knowledge regarding the use of survivin and its isoforms in prognosis and treatment of breast cancer. An advanced search of Medline was performed using the following search strategy: "(survivin isoforms) OR (survivin transcript variants) AND (breast cancer) AND (neoplasm OR tumor OR cancer OR carcinoma)". Relevant studies were retrieved and processed thoroughly in order to analyze the related data. Besides wild-type survivin full-length transcript, another six splice variants have been identified. Overexpression of survivin and its isoforms leads to shorter overall and disease-free survival; the transcript variants are correlated with apoptosis and could assist prognosis prediction. It has been proved through numerous studies that inhibiting survivin isoforms might become a promising target of drug therapy of carcinomas. Use of small molecule YM155 could offer new therapy for triple negative breast cancer patients, while, chemotherapy with 5-fluorouracil + epirubicin + cyclophosphamide and Tax-Epi could be guided by survivin splice variants measurements. Survivin transcript variants could become prognostic biomarkers and could provide information about clinical management of patients suffering from breast cancer.

Keywords: Breast cancer; Isoforms; Prognosis; Survivin gene; Therapy

References

  1. Clin Chem. 2006 Sep;52(9):1693-700 - PubMed
  2. Sci Signal. 2009 Mar 24;2(63):pe15 - PubMed
  3. Endocr Relat Cancer. 2011 Dec 01;18(6):783-92 - PubMed
  4. Biol Pharm Bull. 2013;36(12):1921-7 - PubMed
  5. J Exp Clin Cancer Res. 2012 Jun 19;31:58 - PubMed
  6. Int J Mol Med. 2009 Feb;23(2):285-91 - PubMed
  7. Biomark Cancer. 2013 Oct 29;5:61-70 - PubMed
  8. J Mammary Gland Biol Neoplasia. 2011 Apr;16(1):3-15 - PubMed
  9. Future Oncol. 2012 Aug;8(8):907-9 - PubMed
  10. Am J Pathol. 2008 Aug;173(2):575-85 - PubMed
  11. Carcinogenesis. 2012 Dec;33(12 ):2311-9 - PubMed
  12. Clin Cancer Res. 2008 Aug 15;14(16):5000-5 - PubMed
  13. Biochim Biophys Acta. 2013 Jan;1835(1):11-27 - PubMed
  14. Nature. 2011 Sep 11;478(7367):64-9 - PubMed
  15. Anticancer Res. 2012 Feb;32(2):397-404 - PubMed
  16. J Cell Mol Med. 2011 Jul;15(7):1542-50 - PubMed
  17. Breast Cancer Res. 2010;12(4):R47 - PubMed
  18. World J Gastroenterol. 2011 Mar 28;17(12):1614-21 - PubMed
  19. Int J Biochem Cell Biol. 2013 Sep;45(9):2036-44 - PubMed
  20. Clin Cancer Res. 2010 Nov 1;16(21):5222-32 - PubMed
  21. Br J Cancer. 2005 Jan 17;92(1):120-4 - PubMed
  22. Gynecol Oncol. 2007 Jan;104(1):139-44 - PubMed
  23. Breast Cancer Res Treat. 2013 Jul;140(1):83-92 - PubMed
  24. Surg Oncol. 2012 Jun;21(2):125-31 - PubMed
  25. Br J Cancer. 2006 Jan 16;94(1):108-14 - PubMed
  26. Nature. 2008 Apr 3;452(7187):564-70 - PubMed
  27. Strahlenther Onkol. 2007 Nov;183(11):593-9 - PubMed
  28. Clin Breast Cancer. 2014 Apr;14(2):122-31 - PubMed
  29. Chem Biol. 2012 Aug 24;19(8):937-54 - PubMed
  30. J Biol Chem. 2008 Sep 5;283(36):25057-73 - PubMed
  31. Clin Chem Lab Med. 2011 Dec 23;50(3):423-34 - PubMed
  32. N Engl J Med. 2004 Dec 30;351(27):2817-26 - PubMed
  33. J Biophotonics. 2012 Apr;5(4):345-66 - PubMed
  34. J Cancer Res Clin Oncol. 2012 Jul;138(7):1205-20 - PubMed
  35. Cell Cycle. 2007 Jun 15;6(12 ):1502-9 - PubMed
  36. Nature. 2008 Nov 27;456(7221):470-6 - PubMed
  37. Biomol Ther (Seoul). 2013 Jan;21(1):29-34 - PubMed
  38. Int J Oncol. 2011 Sep;39(3):569-75 - PubMed
  39. BioDrugs. 2014 Feb;28(1):27-39 - PubMed
  40. J Natl Cancer Inst. 2013 May 15;105(10):701-10 - PubMed
  41. Eur J Cell Biol. 2013 Aug-Sep;92(8-9):247-56 - PubMed
  42. Jpn J Cancer Res. 2000 Nov;91(11):1204-9 - PubMed
  43. Cancer. 2001 Jun 1;91(11):2026-32 - PubMed
  44. Cancer Biol Ther. 2004 Feb;3(2):173-9 - PubMed
  45. Drug Discov Today. 2009 Mar;14(5-6):298-305 - PubMed
  46. Mol Cancer. 2005 Mar 02;4(1):11 - PubMed
  47. N Engl J Med. 2002 Dec 19;347(25):1999-2009 - PubMed
  48. Drug Discov Ther. 2011 Dec;5(6):293-8 - PubMed
  49. Eur J Cancer. 2010 Jan;46(2):298-311 - PubMed
  50. Lancet Oncol. 2010 Jan;11(1):55-65 - PubMed
  51. Leuk Lymphoma. 2006 Jun;47(6):978-85 - PubMed
  52. Folia Histochem Cytobiol. 2011;49(1):26-33 - PubMed
  53. Am J Pathol. 2011 Aug;179(2):555-63 - PubMed
  54. Nat Rev Drug Discov. 2010 Oct;9(10):775-89 - PubMed
  55. Genes Chromosomes Cancer. 2010 Dec;49(12 ):1135-42 - PubMed
  56. Cell. 2010 Aug 20;142(4):625-36 - PubMed
  57. DNA Seq. 2005 Oct;16(5):321-8 - PubMed
  58. Breast Cancer Res. 2013 Mar 14;15(2):R24 - PubMed

Publication Types